Although some analysts and industry experts believe biotech firms enjoy an elevated premium or valuation, M&A in the space is growing. As a result, small companies have become the target of the big companies.
Most recently, Pfizer acquired Medivation Inc MDVN for $14 billion on August 22. Within the next few days, the company bought AstraZeneca plc (ADR) AZN's antibiotics portfolio for $1.5 billion. There are also a number of small companies that announced M&A in the current year.
Below is a look at the big mergers in the current year.
- Abbott Laboratories ABT announced an agreement to buy Alere Inc. ALR for $5.8 billion on February 1. However, Alere has since announced that it is suing Abbot over the merger deal. Abbott has refuted the complaints and is "continuing with its efforts to acquire regulatory approvals."
- Gilead Sciences, Inc. GILD announced the acquisition of Nimbus Apollo, Inc., which was a wholly-owned subsidiary of Nimbus Therapeutics, and its Acetyl-CoA Carboxylase inhibitor program for $1.2 billion on April 4.
- AbbVie Inc ABBV announced it would acquire Stemcentrx for $5.8 billion on April 28.
- Jazz Pharmaceuticals plc - Ordinary Shares JAZZ bought Celator Pharmaceuticals Inc (previously traded on the NASDAQ under the ticker CPXX) for $1.5 billion cash announced May 31.
- Cinven went into an agreement to acquire BioClinica for $1.4 billion on August 22.
- Pfizer buys Medivation for $14 billion on August 22.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.